✕
Login
Register
Back to News
Summit Therapeutics Q1 Adj. EPS $(0.15) Beats $(0.18) Estimate
Benzinga Newsdesk
www.benzinga.com
Negative 50.1%
Neg 50.1%
Neu 0%
Pos 0%
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment